Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis

Taiqin Chen; Ki Yeol Kim; Yeongjoo Oh; Hei Cheul Jeung; Kee Yang Chung; Mi Ryung Roh; Xianglan Zhang

doi:10.3390/cancers14082038

Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis

Taiqin Chen, Ki Yeol Kim, Yeongjoo Oh, Hei Cheul Jeung, Kee Yang Chung, Mi Ryung Roh, Xianglan Zhang

Department of Dermatology

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The underlying molecular mechanisms of cutaneous squamous cell carcinoma (cSCC) pathogenesis are largely unknown. In the present study, we aimed to evaluate the effect of coatomer protein complex subunit beta 2 (COPB2) expression on cSCC pathogenesis. Clinicopathological significance of COPB2 in cSCC was investigated by analyzing the Gene Expression Omnibus (GEO) database and through a retrospective cohort study of 95 cSCC patients. The effect of COPB2 expression on the biological behavior of cSCC cells was investigated both in vitro and in vivo. We found that COPB2 expression was significantly higher in cSCC samples than in normal skin samples. In our cohort, a considerable association was found between COPB2 expression and indicators of tumor immune microenvironment (TIME), such as histocompatibility complex class (MHC) I, and MHC II, CD4+/ CD8+ tumor-infiltrating lymphocytes. Additionally, COPB2 expression had an independent impact on worsened recurrence-free survival in our cohort. Furthermore, decreased proliferation, invasion, tumorigenic activities, and increased apoptosis were observed after COPB2 knockdown in cSCC cells. COPB2 may act as a potential oncogene and candidate modulator of the TIME in cSCC. Therefore, it can serve as a novel predictive prognostic biomarker and candidate immunotherapeutic target in cSCC patients.

Original language	English
Article number	2038
Journal	Cancers
Volume	14
Issue number	8
DOIs	https://doi.org/10.3390/cancers14082038
Publication status	Published - 2022 Apr 1

Bibliographical note

Funding Information:
Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2020R1I1A1A01073437, No. 2021R1I1A1A01048175, No. 2020R1A2C1102987, No. 2017R1D1A1B03034921, and No. 2021R1A2C1094638), and by a grant from National Natural Science Foundation of China (NSFC, No. 81460408).

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers14082038

Cite this

@article{5b2c6f4f892b459d9078e5cdaafa2c95,

title = "Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis",

abstract = "The underlying molecular mechanisms of cutaneous squamous cell carcinoma (cSCC) pathogenesis are largely unknown. In the present study, we aimed to evaluate the effect of coatomer protein complex subunit beta 2 (COPB2) expression on cSCC pathogenesis. Clinicopathological significance of COPB2 in cSCC was investigated by analyzing the Gene Expression Omnibus (GEO) database and through a retrospective cohort study of 95 cSCC patients. The effect of COPB2 expression on the biological behavior of cSCC cells was investigated both in vitro and in vivo. We found that COPB2 expression was significantly higher in cSCC samples than in normal skin samples. In our cohort, a considerable association was found between COPB2 expression and indicators of tumor immune microenvironment (TIME), such as histocompatibility complex class (MHC) I, and MHC II, CD4+/ CD8+ tumor-infiltrating lymphocytes. Additionally, COPB2 expression had an independent impact on worsened recurrence-free survival in our cohort. Furthermore, decreased proliferation, invasion, tumorigenic activities, and increased apoptosis were observed after COPB2 knockdown in cSCC cells. COPB2 may act as a potential oncogene and candidate modulator of the TIME in cSCC. Therefore, it can serve as a novel predictive prognostic biomarker and candidate immunotherapeutic target in cSCC patients.",

author = "Taiqin Chen and Kim, {Ki Yeol} and Yeongjoo Oh and Jeung, {Hei Cheul} and Chung, {Kee Yang} and Roh, {Mi Ryung} and Xianglan Zhang",

note = "Funding Information: Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2020R1I1A1A01073437, No. 2021R1I1A1A01048175, No. 2020R1A2C1102987, No. 2017R1D1A1B03034921, and No. 2021R1A2C1094638), and by a grant from National Natural Science Foundation of China (NSFC, No. 81460408). Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = apr,

day = "1",

doi = "10.3390/cancers14082038",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

TY - JOUR

T1 - Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis

AU - Chen, Taiqin

AU - Kim, Ki Yeol

AU - Oh, Yeongjoo

AU - Jeung, Hei Cheul

AU - Chung, Kee Yang

AU - Roh, Mi Ryung

AU - Zhang, Xianglan

N1 - Funding Information: Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2020R1I1A1A01073437, No. 2021R1I1A1A01048175, No. 2020R1A2C1102987, No. 2017R1D1A1B03034921, and No. 2021R1A2C1094638), and by a grant from National Natural Science Foundation of China (NSFC, No. 81460408). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - The underlying molecular mechanisms of cutaneous squamous cell carcinoma (cSCC) pathogenesis are largely unknown. In the present study, we aimed to evaluate the effect of coatomer protein complex subunit beta 2 (COPB2) expression on cSCC pathogenesis. Clinicopathological significance of COPB2 in cSCC was investigated by analyzing the Gene Expression Omnibus (GEO) database and through a retrospective cohort study of 95 cSCC patients. The effect of COPB2 expression on the biological behavior of cSCC cells was investigated both in vitro and in vivo. We found that COPB2 expression was significantly higher in cSCC samples than in normal skin samples. In our cohort, a considerable association was found between COPB2 expression and indicators of tumor immune microenvironment (TIME), such as histocompatibility complex class (MHC) I, and MHC II, CD4+/ CD8+ tumor-infiltrating lymphocytes. Additionally, COPB2 expression had an independent impact on worsened recurrence-free survival in our cohort. Furthermore, decreased proliferation, invasion, tumorigenic activities, and increased apoptosis were observed after COPB2 knockdown in cSCC cells. COPB2 may act as a potential oncogene and candidate modulator of the TIME in cSCC. Therefore, it can serve as a novel predictive prognostic biomarker and candidate immunotherapeutic target in cSCC patients.

AB - The underlying molecular mechanisms of cutaneous squamous cell carcinoma (cSCC) pathogenesis are largely unknown. In the present study, we aimed to evaluate the effect of coatomer protein complex subunit beta 2 (COPB2) expression on cSCC pathogenesis. Clinicopathological significance of COPB2 in cSCC was investigated by analyzing the Gene Expression Omnibus (GEO) database and through a retrospective cohort study of 95 cSCC patients. The effect of COPB2 expression on the biological behavior of cSCC cells was investigated both in vitro and in vivo. We found that COPB2 expression was significantly higher in cSCC samples than in normal skin samples. In our cohort, a considerable association was found between COPB2 expression and indicators of tumor immune microenvironment (TIME), such as histocompatibility complex class (MHC) I, and MHC II, CD4+/ CD8+ tumor-infiltrating lymphocytes. Additionally, COPB2 expression had an independent impact on worsened recurrence-free survival in our cohort. Furthermore, decreased proliferation, invasion, tumorigenic activities, and increased apoptosis were observed after COPB2 knockdown in cSCC cells. COPB2 may act as a potential oncogene and candidate modulator of the TIME in cSCC. Therefore, it can serve as a novel predictive prognostic biomarker and candidate immunotherapeutic target in cSCC patients.

UR - http://www.scopus.com/inward/record.url?scp=85128397104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128397104&partnerID=8YFLogxK

U2 - 10.3390/cancers14082038

DO - 10.3390/cancers14082038

M3 - Article

AN - SCOPUS:85128397104

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 8

M1 - 2038

ER -

Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this